Board Meeting Materials
Agenda Item II. Discussion and Possible Action Related to Proposed Regulations, Title 16, California Code of Regulations, Repeal of Sections 1708.3, 1708.4, 1735 et seq., and 1751 et seq. and Addition of Sections 1735 et seq., 1736 et seq., 1737 et seq., and 1738 et seq. Related to Compounded Drug Preparations, Hazardous Drugs, and Radiopharmaceuticals, Including Review of Comments Received During the 15-Day Comment Period
Staff Recommended Responses
Section 1735 et seq (Nonsterile)
Section 1736 et seq (Sterile)
Section 1737 et seq (Hazardous)
Section 1738 et seq (Radiopharmaceuticals)
General Comments
Comments Received During the 15-Day Comment Period
Comments
Agenda Item VII. Approval of Board Meeting Minutes
a. November 6-7, 2024 Board Meeting
b. December 4, 2024 Board Meeting
c. December 18, 2024 Disciplinary Petition Committee Meeting
d. January 8, 2025 Board Meeting
Agenda Item IX. Presentation by the Office of the Attorney General on the Disciplinary Process
Agenda Item X. Presentation - Addressing the Crisis: Improving Addiction Medicine Access at
Pharmacies. Presenters include Hector De Leon; Brian Hurley, MD; Gillmore Chung, MD; Aimee Moulin, MD and Casey Alrich
Agenda Item XI. Presentation on Proposed Follow-up Statewide Study to Describe Trends and Access to
PrEP in California. Presenters include Stefano Bertozzi, MD PhD; Jerika Lam, PharmD,
Ayako Miyashita Ochoa, JD and Lauren Hunter PhD.
Agenda Item XII. Discussion and Consideration of Waiver of Pharmacy Law Provisions Consistent with the
Authority in Business and Professions Code Section 4062 in Response to State of Emergency Related to the Palisades Fire” The naming convention truncated the name of the file.
Agenda Item XIII. Organizational Development Committee Report
a. Budget Report
b. Board Member Attendance and Mail Vote Information
c. Personnel Update
d. Future Meeting Dates
Agenda Item XIV. Executive Officer Report
Written Comments 1
Written Comments 2
Written Comments 3
Written Comments 4
Written Comments 5
